D.E. Shaw & Co
RYTM icon

D.E. Shaw & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

D.E. Shaw & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Sell
30,168
-2,484
-8% -$225K ﹤0.01% 2745
2026
Q1 		$2.84M Buy
32,652
+1,296
+4% +$126K ﹤0.01% 2638
2025
Q4 		$3.36M Buy
31,356
+27,771
+775% +$2.95M ﹤0.01% 2642
2025
Q3 		$362K Sell
3,585
-20,693
-85% -$1.92M ﹤0.01% 4021
2025
Q2 		$1.53M Sell
24,278
-59,591
-71% -$3.65M ﹤0.01% 2930
2025
Q1 		$4.44M Buy
83,869
+35,671
+74% +$1.98M ﹤0.01% 1983
2024
Q4 		$2.7M Buy
48,198
+43,904
+1,022% +$2.43M ﹤0.01% 2495
2024
Q3 		$225K Buy
+4,294
New +$206K ﹤0.01% 4107
2024
Q2 		– Sell
-10,462
Closed -$453K – 4801
2024
Q1 		$453K Sell
10,462
-118,030
-92% -$5.17M ﹤0.01% 3539
2023
Q4 		$5.91M Buy
+128,492
New +$4.05M 0.01% 1780
2023
Q2 		– Sell
-278,203
Closed -$4.96M – 4509
2023
Q1 		$4.96M Sell
278,203
-77,327
-22% -$1.94M 0.01% 1944
2022
Q4 		$10.4M Buy
355,530
+172,461
+94% +$4.43M 0.01% 1396
2022
Q3 		$4.49M Buy
183,069
+146,577
+402% +$2.73M 0.01% 2223
2022
Q2 		$151K Sell
36,492
-60,493
-62% -$331K ﹤0.01% 4637
2022
Q1 		$1.12M Buy
+96,985
New +$851K ﹤0.01% 3824
2021
Q2 		– Sell
-31,653
Closed -$673K – 4983
2021
Q1 		$673K Buy
+31,653
New +$918K ﹤0.01% 3364
2019
Q1 		– Sell
-10,982
Closed -$295K – 3878
2018
Q4 		$295K Sell
10,982
-41,179
-79% -$1.14M ﹤0.01% 3356
2018
Q3 		$1.52M Buy
52,161
+14,586
+39% +$461K ﹤0.01% 2391
2018
Q2 		$1.18M Buy
+37,575
New +$1.03M ﹤0.01% 2606

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co's RYTM Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Rhythm Pharmaceuticals (RYTM) stake by 7.6% in Q2 2026, selling an estimated $225K and leaving 30,168 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

D.E. Shaw & Co first reported a position in RYTM in Q2 2018 and has held it in 19 quarters since. The position peaked at $10.4M in Q4 2022. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • D.E. Shaw & Co held 30,168 shares of Rhythm Pharmaceuticals worth $3.35M as of Q2 2026.
  • D.E. Shaw & Co sold 2,484 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2745 holding.
  • D.E. Shaw & Co first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.